IFNA1 and COVID-19: Given our lack of “baseline” samples from individuals prior to their infection with SARS-CoV-2, and the fact that our earliest samples are from admittance to ICU (likely a late event in disease progression), it is impossible to conclude whether these anti-IFN autoantibodies preexisted in these individuals prior to COVID-19.